The only accredited stem cell transplant and cellular therapy programme in New Mexico, based at the University of New Mexico Comprehensive Cancer Center in Albuquerque.
This is the Transplant and Cellular Therapies programme of the University of New Mexico Comprehensive Cancer Center in Albuquerque, also referred to on the site as the Bone Marrow and Stem Cell Transplant Center. It is a hospital-based academic programme rather than a private clinic, and the site states it is the only stem cell transplant and cellular therapy programme in New Mexico. It sits within a cancer centre designated as comprehensive by the National Cancer Institute.
This is also a fundamentally different kind of cell therapy from most entries in this directory. Stem cell transplantation for blood cancers is established, evidence-based hospital treatment with decades of use, delivered under formal accreditation - the site states the programme is accredited by the Foundation for the Accreditation of Cellular Therapy. It is not a privately sold injection for joint pain. The treatments named are autologous stem cell transplant (using the patient's own cells), allogeneic stem cell transplant (using cells from a donor), and CAR T cell therapy, in which the patient's own T lymphocytes - a type of white blood cell - are genetically modified to recognise tumour cells before being returned to them.
The site explains the process in useful practical detail. For an autologous transplant the patient's own stem cells are collected and frozen, then given back after high-dose chemotherapy. Collection is usually from the bloodstream rather than the bone marrow itself: medication, typically filgrastim, is given to move stem cells from the marrow into the circulation, and the cells are then separated out by a machine in an outpatient procedure called apheresis, described as taking three to four hours. For an allogeneic transplant the cells come from a donor, typically a close relative, which the site notes removes the risk of tumour cells being reinfused and supplies a new immune system, at the cost of needing immune-suppressing medication afterwards.
The conditions treated are blood cancers and bone marrow disorders: lymphoma and myeloma, usually with autologous transplant; leukaemia and other blood and marrow diseases, usually with allogeneic transplant; and blood cancers that have not responded to other treatment, for CAR T cell therapy. The programme also provides long-term follow-up, including management of chronic graft-versus-host disease, and offers access to clinical trials through the SWOG and ECOG research networks. Matthew Fero, MD, FACP, is named as programme director, and there is a dedicated inpatient unit, 5 East. The site indicates that services are available in English and Spanish. As a hospital programme, cost is handled through insurance and hospital billing rather than published prices.
The programme treats blood cancers and disorders of the bone marrow; these are the diseases for which stem cell transplantation is established treatment.
The site describes three established forms of cellular therapy: transplant using the patient's own blood stem cells, transplant using a donor's, and genetically modified immune cells made from the patient's own white blood cells.
The site names the programme director; as a university hospital programme it is staffed by a wider transplant team.
The programme is based at the University of New Mexico Comprehensive Cancer Center at 1201 Camino de Salud Northeast in Albuquerque, in the university's health sciences district. It has a dedicated inpatient unit identified on the site as 5 East, with outpatient apheresis for stem cell collection, and sits inside a cancer centre designated as comprehensive by the National Cancer Institute. The site states the programme holds accreditation from the Foundation for the Accreditation of Cellular Therapy, the body that accredits transplant and cell therapy programmes in North America - a meaningful external check that private cell clinics rarely have.
No prices are published, which is normal for a university hospital programme. Treatment of this kind in the United States is billed through health insurance and hospital financial services rather than sold at a list price, and the programme's financial counsellors would handle coverage and out-of-pocket costs. This differs from the private pay model used by most clinics in this directory.
Profile compiled from information published on the clinic's own website and from the StemCell Registry directory record. Details may change; confirm directly with the clinic before making decisions.